Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction

New England Journal of Medicine

Volumn 327, Issue 1, 1992, Pages 7-13

  Krumholz, Harlan M ^a,b   Pasternak, Richard C ^a,b   Weinstein, Milton C ^a,c,d   Friesinger, Gottlieb C ^a,c,e   Ridker, Paul M ^a,c   Tosteson, Anna N a ^a,b,c,d   Goldman, Lee ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; HUMAN; LIFE EXPECTANCY; MODEL; MORTALITY; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT;

EID: 0026740917     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199207023270102     Document Type: Article

References (26)

1. Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med 1990; 113: 949–60.
2. Grines CL, DeMaria AN. Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies. J Am Coll Cardiol 1990; 16: 223–31.
3. Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA 1991; 265: 1720–3.
4. Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 4th ed. Philadelphia: W.B. Saunders, 1992:1232.
5. Sherry S, Marder VJ. Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderly. J Am Coll Cardiol 1991; 17: 1237–8.
6. Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. J Am Coll Cardiol 1990; 16: 249–92.
7. Pfeffer MA, Moyé LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991; 266: 528–32.
8. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991; 115: 173–7.
9. Goldman L, Cook EF, Brand DA, et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med 1988; 318: 797–803.
10. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–402.
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
12. ISIS Collaborative Group. Optimizing thrombolytic therapy of acute myocardial infarction: age is not a contraindication. Circulation 1991; 84: Suppl II: II-230.
13. O'Connor CM, Califf RM, Massey EW, et al. Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. J Am Coll Cardiol 1990; 16: 533–40.
14. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987; 2: 871–4.
15. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987; 77: 1417–26.
16. Hodgson TA, Kopstein AN. Health care expenditures for major diseases in 1980. Health Care Financ Rev 1984; 5(4):1–12.
17. U.S. Senate Special Committee on Aging. Aging America: trends and projections. Washington. D.C.: Department of Health and Human Services, 1988.
18. Goldberg RJ, Gore JM, Gurwitz JH, et al. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 1989; 117: 543–9.
19. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Incidence and case fatality rates of acute myocardial infarction (1975–1984): the Worcester Heart Attack Study. Am Heart J 1988; 115: 761–7.
20. Roig E, Castaner A, Simmons B, Patel R, Ford E, Cooper R. In-hospital mortality rates for acute myocardial infarction by race in U.S. hospitals: findings from the National Hospital Discharge Survey. Circulation 1987; 76: 280–8.
21. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545–9.
22. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525–30.
23. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. Ann Intern Med 1990; 112: 192–202.
24. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991; 18: 657–62.
25. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989; 320: 618–27.
26. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990; 335: 427–31.